<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>18 Bone marrow failure</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-17-haemolytic-anaemias-V-inherited-defects-of-haemoglobin-sickle-cell-disease.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 45%;"></div>
                        </div>
                       <span class="progress-text">Lecture 18 of 40</span>
                    </div>
                    <a href="haematology-19-haematological-malignancy-basic-mechanisms.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">18 Bone marrow failure</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="bmd-intro" class="content-section" aria-labelledby="section-heading-1">
                    <div class="content-card">
                        <p>Bone marrow failure is the failure of the bone marrow to produce sufficient red cells, white cells and platelets. Causes are listed in Table 18.1. The bone marrow may be hypoplastic or aplastic, with a reduction in haemopoietic cells and an increase in fat spaces. Alternatively, the haemopoietic cells may be replaced by abnormal cells or malignant cells either arising in the marrow (primary) or infiltrating it (secondary).</p>
                        
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 18.1 Bone marrow failure.</caption>
                                <tbody>
                                    <tr><td><strong>Primary reduction in haemopoietic cells</strong></td></tr>
                                    <tr><td>Aplastic anaemia</td></tr>
                                    <tr><td><strong>Replacement of marrow by malignant cells</strong></td></tr>
                                    <tr><td>Primary-leukaemia, myeloma, lymphoma<br>Secondary-e.g. carcinoma</td></tr>
                                    <tr><td><strong>Ineffective haemopoiesis</strong></td></tr>
                                    <tr><td>Myelodysplasia, megaloblastic anaemia</td></tr>
                                    <tr><td><strong>Infiltration by abnormal tissue</strong></td></tr>
                                    <tr><td>Myelofibrosis<br>Rarely, Gaucher's disease, amyloidosis, osteopetrosis</td></tr>
                                </tbody>
                            </table>
                        </div>

                        <h3 class="subsection-heading">Clinical features</h3>
                        <ul>
                            <li>Symptoms and signs of anaemia, infections and easy bruising or bleeding.</li>
                            <li>Symptoms and signs as a result of the underlying cause, e.g. side effects of chemotherapy.</li>
                        </ul>

                        <h3 class="subsection-heading">Laboratory findings</h3>
                        <ul>
                            <li>Anaemia, leucopenia and thrombocytopenia of varying severity.</li>
                            <li>Blood film may show circulating red cell and white precursors (leucoerythroblastic) caused by bone marrow infiltration (see Chapter 34) or may show evidence of primary haematological malignancy, e.g. circulating leukaemic blast cells.</li>
                            <li>Bone marrow aspirate and trephine biopsy are required to define cause (Fig. 18.1).</li>
                        </ul>

                        <h3 class="subsection-heading">Differential diagnosis</h3>
                        <ul>
                            <li>Pancytopenia (reduction in all three haemopoietic cell lines) can also result from accelerated destruction of cells (e.g. as a result of splenomegaly or autoimmune destruction) or pooling of cells (e.g. within an enlarged spleen).</li>
                        </ul>

                        <h3 class="subsection-heading">Treatment</h3>
                        <ul>
                            <li>Remove any known cause, e.g. drugs.</li>
                            <li>Support care with appropriate blood components (see Chapter 37) and antimicrobials (see Chapter 39).</li>
                            <li>Specific therapy is considered separately with the specific diseases.</li>
                        </ul>
                    </div>
                </section>

                <section id="aplastic-anaemia" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Aplastic anaemia</span>
                    </h2>
                    <div class="content-card">
                        <p>This is a chronic pancytopenia associated with a hypoplastic bone marrow. There are reduced marrow stem cells, increased fat spaces (fat/haemopoiesis ratio >75:25%) and no evidence of malignancy. The marrow microenvironment is intact.</p>
                        
                        <h3 class="subsection-heading">Aetiology and pathogenesis</h3>
                        <p>The disease may be congenital or acquired (Table 18.2).</p>
                        <ul>
                            <li>Congenital aplastic anaemia may be inherited as an autosomal recessive (Fanconi type); rarely associated with dyskeratosis congenita.</li>
                            <li>Acquired aplastic anaemia has an identifiable cause (viral infection, radiation or drug exposure) in about $50\%$ of cases. In the remainder the cause is unknown, but may involve an immune reaction against marrow stem cells.</li>
                        </ul>
                        
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 18.2 Causes of aplastic anaemia.</caption>
                                <tbody>
                                    <tr>
                                        <td><strong>Congenital</strong></td>
                                        <td>Fanconi<br>Other, e.g. dyskeratosis congenita</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Acquired</strong></td>
                                        <td>Idiopathic<br>Secondary<br>Inevitable (cytotoxic drugs, radiation)<br>Idiosyncratic<br>Drugs, e.g. chlorampenicol, sulphonamides, gold, chlorpromazine, carbimazole<br>Chemical agents/toxins, e.g. benzene<br>Infection, e.g. viral hepatitis (non-A, non-B, non-C)<br>Associated with haematological malignancy, e.g. acute lymphoblastic leukaemia<br>Other, e.g. in association with paroxysmal nocturnal haemoglobinuria</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3 class="subsection-heading">Clinical features</h3>
                        <ul>
                            <li>May occur at any age, in either sex, incidence of 2-5 cases/million population.</li>
                            <li>Onset rapid (over a few days) or slow (over weeks or months).</li>
                            <li>Symptoms and signs are caused by bone marrow failure (see above).</li>
                            <li>Liver, spleen and lymph nodes are not enlarged.</li>
                            <li>Fanconi's anaemia (Fig.18.2) usually presents in childhood. Associated findings may include skeletal and renal tract defects, microcephaly and altered skin pigmentation. In dyskeratosis congenita there are skin, hair and nail changes.</li>
                        </ul>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-052-1.jpg" alt="Fig. 18.1 Two micrographs of bone marrow in aplastic anaemia: (a) aspirate and (b) trephine biopsy, both showing reduced cellularity and increased fat spaces." class="content-image" style="width:100%;">
                            <figcaption>Fig. 18.1 Aplastic anaemia: (a) bone marrow aspirate; and (b) trephine biopsy showing reduced cellularity with increased fat spaces.</figcaption>
                        </figure>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-052-2.jpg" alt="Fig. 18.2 Photograph of a patient with Fanconi's anaemia showing multiple skeletal deformities of the upper limbs." class="content-image">
                            <figcaption>Fig. 18.2 Aplastic anaemia: Fanconi's anaemia, with multiple skeletal deformities of upper limbs.</figcaption>
                        </figure>

                        <h3 class="subsection-heading">Laboratory findings</h3>
                        <ul>
                            <li>Anaemia is normocytic or mildly macrocytic with a low reticulocyte count.</li>
                            <li>Leucopenia is usual with neutrophils below $1.5 \times 10^{9} / \mathrm{L}$ (&lt;0.2 x 10<sup>9</sup>/L in severe cases).</li>
                            <li>Thrombocytopenia (&lt;10 x 10<sup>9</sup>/L in severe cases).</li>
                            <li>Bone marrow is hypoplastic with &gt;75% fat spaces. Remaining haemopoietic cells are of normal appearance. Megakaryocytes are particularly reduced.</li>
                            <li>In Fanconi's anaemia lymphocyte chromosomes show random breaks.</li>
                        </ul>

                        <h3 class="subsection-heading">Specific therapy</h3>
                        <ul>
                            <li>Immunosuppression, e.g. antilymphocyte globulin (ALG), horse or rabbit, given intravenously over several days, corticosteroids and cyclosporin (alone or with ALG) improve marrow function in 50-70% of severe cases.</li>
                            <li>Androgens (e.g. oxymetholone) may benefit Fanconi's anaemia and acquired aplastic anaemia.</li>
                            <li>Bone marrow transplantation offers a cure in severe cases, providing there is an HLA matching sibling to act as donor. Results are best (60-70% cure) in younger patients (&lt;20 years).</li>
                            <li>Haemopoietic growth factors, granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor may raise the neutrophil count temporarily but have no long-term benefit on the underlying bone marrow defect.</li>
                        </ul>
                    </div>
                </section>

                <section id="red-cell-aplasia" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Red cell aplasia</span>
                    </h2>
                    <div class="content-card">
                        <p>Red cell aplasia is anaemia caused by selective reduction of red cell production by the bone marrow. There is absence or severe reduction of developing erythroblasts in the marrow and of reticulocytes in the peripheral blood, with no abnormality in other cell lines.</p>
                        
                        <h3 class="subsection-heading">Clinical and laboratory features</h3>
                        <p>A rare congenital form (Diamond-Blackfan anaemia) is frequently associated with other somatic malformations. Acquired red cell aplasia may occur as a result of drugs (e.g. azathioprine, isoniazid), in association with autoimmune diseases (e.g. systemic lupus erythematosus), haematological malignancy (e.g. chronic lymphocytic leukaemia) or with a thymoma (see Chapter 34).</p>
                        <p>Transient red cell aplasia occurs following infection with B19 parvovirus and can lead to a profound but temporary reduction of red cell production with severe anaemia in patients with a haemolytic disorder (e.g. 'aplastic crisis' in hereditary spherocytosis or sickle cell anaemia).</p>
                        
                        <h3 class="subsection-heading">Treatment</h3>
                        <p>Treatment of the underlying disorder (e.g. surgical removal of a thymoma) is required. Red cell transfusion and iron chelation therapy may be required. Immunosuppressive therapy (e.g. prednisolone, cyclosporin, ALG) is useful in selected patients with either congenital or acquired red cell aplasia.</p>
                    </div>
                </section>

                <section id="congenital-dyserythropoietic-anaemias" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                        <span class="heading-text">Congenital dyserythropoietic anaemias</span>
                    </h2>
                    <div class="content-card">
                        <p>Congenital dyserythropoietic anaemias are a rare group of recessively inherited conditions in which chronic anaemia results from abnormal maturation of erythroid cells in the marrow. Red cell precursors usually show marked morphological abnormalities, e.g. bi- and trinucleated normoblasts.</p>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-17-haemolytic-anaemias-V-inherited-defects-of-haemoglobin-sickle-cell-disease.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 45%;"></div>
                        </div>
                       <span class="progress-text">Lecture 18 of 40</span>
                    </div>
                    <a href="haematology-19-haematological-malignancy-basic-mechanisms.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>